Delanzomib

Delanzomib (CAS 847499-27-8), also referenced in research and procurement channels as CEP-18770, is a proteasome inhibitor developed for oncology research applications. CT-47098 is another catalog identifier used by suppliers in the life sciences sector.

It targets the 20S proteasome complex and is evaluated in the context of hematological malignancy research programs. Delanzomib is sourced primarily by pharmaceutical developers and contract research organizations.

These organizations conduct preclinical and clinical studies on multiple myeloma treatment regimens. In drug discovery workflows, it serves as a reference compound for benchmarking novel proteasome inhibitor candidates.

It is benchmarked against established pharmacological profiles. Formulation scientists use it in combination therapy research, particularly alongside agents targeting complementary oncogenic pathways in various studies.

Biotechnology laboratories also procure it as an analytical standard for assay development and biomarker validation studies. Delanzomib is supplied as a solid powder, typically in research-scale quantities.

These quantities range from milligrams to low-gram amounts. Material is generally available at high purity (≥98% by HPLC), consistent with pharmaceutical research and reference standard requirements for the industry.

Material manufactured under GMP standards can be sourced for investigational use. Documentation packages are available to support regulatory submissions and ensure compliance with international safety protocols.